Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

NeuPath Health Inc V.NPTH

NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatrists, endocrinologists, gastroenterologists, general practitioners, internal medicine specialists, neurologists, neuropsychiatrists, neuropsychologists, occupational therapists, ophthalmologists, orthopedic surgeons, physiatrists, physiotherapists, psychologists, respirologists, and rheumatologists. In addition, it operates a network of healthcare clinics and related businesses. The company is headquartered in Mississauga, Canada.


TSXV:NPTH - Post by User

User Avatar Image
(1737)
•••
  • Possibleidiot01X
Post by Possibleidiot01on Dec 04, 2025 7:48am
30 Views
Post# 36810890

NCIB renewal

NCIB renewalPrevious year has to be one of the best executed I've seen with the stock currently at 43 cents.

"Under NeuPath's prior NCIB, which commenced on November 27, 2024 and ended on November 26, 2025, the Company obtained approval to purchase up to a total of 2,820,044 Shares, of which 1,052,300 Shares were purchased for cancellation through the facilities of the Exchange at a volume-weighted average price of approximately C$0.24 (excluding commissions) per Share as of November 24, 2025.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities